Viking Therapeutics, Inc. reported positive outcomes from its phase 2 trial of VK2735, a dual GLP-1 and GIP receptor agonist for metabolic disorders

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder treatments, reported positive outcomes from its phase 2 trial of VK2735, a dual GLP-1 and GIP receptor agonist for metabolic disorders like obesity. The VENTURE trial met primary and secondary endpoints, showing significant body weight reductions in VK2735-treated patients versus placebo, alongside good tolerability. Viking plans discussions with the FDA for further VK2735 development.

Key findings reveal notable body weight reductions with VK2735, up to 14.7% from baseline, and a high proportion of patients achieving ≥10% weight loss compared to placebo. VK2735 demonstrated favorable safety profiles, with mostly mild or moderate adverse events, predominantly gastrointestinal-related.

This randomized, double-blind, placebo-controlled trial assessed VK2735's efficacy and safety over 13 weeks in obese or overweight adults with weight-related comorbidities. Viking Therapeutics focuses on pioneering treatments for metabolic and endocrine disorders, with three compounds undergoing clinical evaluation.